Enhanced Embolic Particles and Delivery Systems for Improved Vascular Defect Occlusion

This inventive concept presents a suite of direct improvements and enhancements to the original embolic particles, including bioactive coatings, biodegradable materials, and advanced delivery systems, to provide safer, more efficient, and more effective occlusion of vascular defects.

The original patent disclosed embolic particles with a first diameter that can fit through a microcatheter and a second expanded diameter once implanted. However, these particles had limitations, such as potential incomplete occlusion, risk of long-term complications, and difficulties in navigating tortuous vasculature. The new inventive concept addresses these limitations by introducing enhanced embolic particles and delivery systems that improve the safety, efficiency, and efficacy of vascular defect occlusion.

The new claims describe a system comprising embolic particles coated with bioactive agents to enhance occlusion, a method for occluding vascular defects using particles that expand to a predetermined size, an embolic particle comprising biodegradable materials, a device for delivering embolic particles with a tapered tip microcatheter, and a kit for occluding vascular defects. These enhancements improve the performance of the original embolic particles by ensuring complete occlusion, reducing the risk of long-term complications, and facilitating navigation through complex vasculature.

The new claims introduce several novel features that distinguish them from the original patent. The use of bioactive coatings, biodegradable materials, and advanced delivery systems provides a significant inventive step, as these features were not contemplated in the original patent. The new claims also provide a more comprehensive solution to the problem of vascular defect occlusion, addressing the limitations of the original patent and providing a safer, more efficient, and more effective treatment option.

Alternative embodiments of the inventive concept could include varying the type and composition of the bioactive coatings, using different biodegradable materials, or incorporating additional features into the delivery device, such as imaging capabilities or sensors to monitor the occlusion process. These variations would ensure broad conceptual coverage and provide a range of options for different clinical scenarios.

The enhanced embolic particles and delivery systems have significant commercial potential in the medical device industry, particularly in the fields of interventional neuroradiology and vascular surgery. The market for vascular defect occlusion devices is growing, driven by the increasing prevalence of aneurysms and other vascular defects. The inventive concept's ability to provide safer, more efficient, and more effective treatment options positions it for success in this market.